REGISTERED NUMBER: 08875847 (England and Wales)

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2024

FOR

EURO OTC PHARMA UK LIMITED

Page

Balance Sheet

1

Notes to the Financial Statements

2

FIXED ASSETS

Tangible assets

4

-

1,013

CURRENT ASSETS

Debtors

5

11,998

17,332

Cash at bank

12,383

8,984

24,381

26,316

CREDITORS

Amounts falling due within one year

6

8,343

10,767

NET CURRENT ASSETS

16,038

15,549

TOTAL ASSETS LESS CURRENT LIABILITIES

16,038

16,562

CAPITAL AND RESERVES

Called up share capital

7

20,000

20,000

Retained earnings

(3,962

)

(3,438

)

SHAREHOLDERS' FUNDS

16,038

16,562

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 April 2025 and were signed on its behalf by:

J F Beyer - Director

1.	STATUTORY INFORMATION

Euro OTC Pharma UK Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number:

08875847

Registered office:

15 West Street

Brighton

East Sussex

BN1 2RL

The presentation currency of the financial statements is the Pound Sterling (£) and have been rounded to the nearest pound.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going concern

The parent company has provided confirmation that for the foreseeable future they will continue to offer Euro OTC Pharma UK Limited financial support. The directors have therefore concluded that these financial statements should be prepared on a going concern basis.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. Turnover comprises consultancy charges for provision of technical and sales support to other group companies.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Plant and machinery

-

33% on cost

Fixtures and fittings

-

20% on cost

Tangible fixed assets are initially measured at cost and subsequently measured at cost, net of depreciation and any impairment losses.

Financial instruments

Basic financial assets

Basic financial assets, which include debtors and cash and cash equivalents, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost, using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Amortised cost is determined as being the transaction price less any amounts settled and any impairment losses. Financial assets classified as receivable within one year are not amortised.

A provision for impairment of debtors is established when there is objective evidence that the amounts due will not be collected according to the original terms of the contract. Impairment losses are recognised in profit or loss for the excess of the carrying value of the trade debtor over the present value of the future cash flows discounted using the original effective interest rate. Subsequent reversals of an impairment loss that objectively relate to an event occurring after the impairment loss was recognised, are recognised immediately in profit or loss.

Basic financial liabilities

Basic financial liabilities, including trade, group and other creditors (including accruals) payable are initially measured at the transaction price and subsequently measured at amortised cost unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as receivable within one year are not amortised.

Taxation

Taxation for the year is comprised of current tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Foreign currencies

Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

Hire purchase and leasing commitments

Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - 1 ).

4.	TANGIBLE FIXED ASSETS

Fixtures

Plant and

and

machinery

fittings

Totals

£

£

£

COST

At 1 January 2024

4,006

1,561

5,567

Disposals

(4,006

)

-

(4,006

)

At 31 December 2024

-

1,561

1,561

DEPRECIATION

At 1 January 2024

2,993

1,561

4,554

Charge for year

1,013

-

1,013

Eliminated on disposal

(4,006

)

-

(4,006

)

At 31 December 2024

-

1,561

1,561

NET BOOK VALUE

At 31 December 2024

-

-

-

At 31 December 2023

1,013

-

1,013

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Amounts owed by group undertakings

8,848

13,549

VAT

-

553

Prepayments and accrued income

3,150

3,230

11,998

17,332

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2024

2023

£

£

Trade creditors

3,757

5,834

Tax

115

461

VAT

53

-

Other creditors

39

39

Accruals and deferred income

4,379

4,433

8,343

10,767

7.	CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number

Class

Nominal

2024

2023

Value:

£

£

20,000

Ordinary

1

20,000

20,000

8.	DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

The Report of the Auditors was unqualified.

Colin Young BA FCA (Senior Statutory Auditor)

for and on behalf of Galloways Accounting

9.	OFF-BALANCE SHEET ARRANGEMENTS

At the year end, the company had non-cancellable operating lease commitments, due less than 5 years, of £2,563 (2023: £12,813).

10.	RELATED PARTY DISCLOSURES

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

11.	PARENT COMPANIES

The immediate and ultimate parent undertaking and controlling party is Beyer Global Healthcare GmbH, which is incorporated in Germany. The registered office of Beyer Global Healthcare GmbH is Edisonstrasse 6, D-59199 Bonen, Germany. The companies results are included in the consolidated financial statements of Beyer Global Healthcare GmbH and consolidated financial statements can be requested from their registered office.